1	The prognostic, p	predictive and clinicopathological impact of KRT81 / HNF1A- and							
2	GATA6- based transcriptional subtyping in pancreatic cancer								
3	Michael Guenther	^{1,2} , Sai Agash Surendran ¹ , Volker Heinemann ³ , Michael Haas ^{3,4} , Stefan							
4	Boeck 3,4 and Steff	fen Ormanns ^{1,2*}							
5									
6	1: Innpath Institute	e of Pathology, Tirol Kliniken, Innsbruck, Austria							
7	2: Institute of Pa	athology, Faculty of Medicine, Ludwig-Maximilians-University, Munich,							
8	Germany								
9	3: Department of I	Internal Medicine III, Grosshadern University Hospital, Ludwig-Maximilians-							
10	University, Munich	ı, Germany							
11	4: Department of H	Hematology and Oncology, München Klinik Neuperlach, Munich, Germany							
12	*: corresponding a	uthor							
13									
14	Figures:	3							
15	Tables:	3							
16	Supplementals:	6 figures, 12 tables							
17	References:	34							
18	Word count								
19	Abstract:	175							
20	Article:	2745							
21									
22	Correspondence:								
23	Steffen Ormanns,	MD (ORCID 0000-0002-0754-9034)							
24	Innpath Institute of	f Pathology – Tirol Kliniken							
25	Anichstraße 35								
26	6020 Innsbruck								
27	Austria								
28	steffen.ormanns@	innpath.at							
29									
30									
31									
32									
33									
34									
35									
36									
37									

1 ABSTRACT

2

3 BACKGROUND

4 Transcriptional subtypes of pancreatic ductal adenocarcinoma (PDAC) have prognostic 5 implications and potential predictive functions. This study aimed to determine their 6 clinicopathological impact in large cohorts of advanced and resected PDAC and their 7 evolution during disease progression.

8

9 METHODS

The clinicopathological and prognostic implications of transcriptional subtypes determined by the expression of KRT81, HNF1A and GATA6 were examined using immunohistochemistry in advanced (n=139) and resected (n=411) PDAC samples as well as in 57 matched primary tumors and corresponding metastases. RNAseq data of 316 resected PDAC patients was analyzed for validation.

15

16 RESULTS

Both subtyping systems were highly interrelated. Subtypes switched during disease progression in up to 31.6% of patients. Transcriptional subtyping had a modest prognostic impact in both unstratified cohorts, but strongly improved outcomes in patients with KRT81 positive / GATA6 negative tumors treated with palliative or adjuvant gemcitabine-based chemotherapy. RNAseq expression data confirmed the findings.

22

23 CONCLUSIONS

24 Transcriptional subtypes have differential responses on palliative and adjuvant gemcitabine-

25 based chemotherapy, but they may change during disease progression. Both employed

subtyping systems are equivalent and can be used to inform clinical therapy decisions.

27

28 CLINICAL TRIAL REGISTRY

29 The clinical trial registry identifier is NCT00440167.

- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37

1 INTRODUCTION

Although modest improvements in the prognosis of pancreatic ductal adenocarcinoma 2 3 (PDAC) patients were achieved in the past years, mainly through innovative randomized 4 control trials (RCT) on novel chemotherapy (CTX) regimens, the survival probability of the average PDAC patients remains desperately low¹, even for patients in early disease stages². 5 6 For the minority of patients diagnosed with resectable disease, adjuvant therapy has become 7 standard of care, with the active but toxic regimen FOLFIRINOX as 1st choice for the clinically fit patient and the less active but less toxic gemcitabine for the less fit³. Large sequencing 8 9 studies have revealed the molecular background of the disease on the genetic as well as the 10 transcriptional level, which resulted in the identification of transcriptional subtypes, based on the expression of specific hallmark genes⁴. Thus, several transcriptional subtyping systems 11 12 were proposed, each of which showed a differential prognostic impact of the subtypes 13 identified⁴. Some studies even proposed prognostic implications of transcriptional subtyping. 14 which largely relied on complex, RNA-based methodologies such as RNA-sequencing 15 (RNAseq), which are hard to establish in routine diagnostics. Therefore, efforts were made to 16 break down complex subtyping systems to simpler approaches applicable in routine clinical 17 practice by detecting the expression of each subtypes' hallmark genes through immunohistochemistry (IHC)^{5,6}. Although these approaches resulted in valuable information 18 19 on the potential clinical implications of the subtypes identified, their meaning to inform clinical decision making was modest at best^{6,7}. Moreover, most studies did not examine the clinical 20 21 significance of transcriptional subtypes with respect to clinicopathological parameters such 22 as disease stage or the therapies applied -specifically in the adjuvant setting- and no study to 23 date compared the different subtyping systems with each other in the same set of samples. 24 Thus, in the present study, we examined the prognostic and potentially predictive impact of 25 the two most employed IHC-based subtyping systems, i.e. the expression of KRT81 and 26 HNF1A or GATA6 respectively, in large cohorts of advanced PDAC and resected PDAC 27 patients, compared both subtyping systems and determined how the metastatic process may 28 affect the predominant subtype.

29

30 MATERIALS and METHODS

The study cohorts and the inclusion and exclusion criteria were described previously⁸. Archival formalin-fixed paraffin embedded (FFPE) histologically confirmed tumor tissue of primary tumors and metastatic tissue was collected from the pathology laboratories where the diagnosis of PDAC was first established. Patients' overall survival (OS), disease free survival (DFS) as well as progression free survival (PFS) was calculated as described before⁸. Written informed consent for the use of tumor material and clinical data was obtained from advanced PDAC patients upon study enrollment or before palliative

3

chemotherapy initiation. The ethics committee of the medical faculty LMU approved the use 1 of patient material and data in the resected PDAC cohort (project 20-081). Tissue microarray 2 3 (TMA) construction was described before⁸. GATA6 expression was detected on four µm thick sections by immunohistochemistry using an anti-GATA6 polyclonal rabbit antibody (PA1-104, 4 Thermo Fisher, Germering, Germany) at a 1:200 dilution. Immunohistochemical detection of 5 6 KRT81 and HNF1A was performed as described previously⁹. Appropriate positive controls 7 were included in each staining run (human normal tonsil for KRT81, duodenal mucosa for 8 HNF1A and normal exocrine pancreas for GATA6, suppl. figure S1 A - C). The expression 9 pattern and expression strength were independently evaluated by two pathologists (MG, SO) 10 blinded to the patient outcome and discrepant cases were discussed until agreement was 11 reached. Tumors were classified as follows: samples with \geq 30% KRT81- or HNF1A-positive 12 tumor cells were considered positive for each marker. For GATA6 expression, tumors with 13 distinct nuclear staining were considered GATA6 positive. Microphotographs were acquired as described previously⁸. Kaplan-Meier curves, Cox regression analyses and cross 14 15 tabulations were computed using SPSS software (IBM, Ehningen, Germany), considering a 16 p-value of ≤ 0.05 as statistically significant. Propensity score matching, as well as the 17 analysis of publicly available gene expression data and the patients' corresponding clinical data was carried out as described before⁸. RNA sequencing data and clinical information of 18 19 the ICGC-CA cohort were downloaded from International Cancer Genome Consortium 20 (ICGC) data portal ¹⁰. Genomic analysis and data visualization was conducted using 21 cBioPortal for Cancer Genomics¹¹.

22

23 RESULTS

Transcriptional subtypes according to the expression of KRT81, HNF1A and GATA6 widely overlap but may change during metastatic progression

26 Of the 139 samples in the advanced PDAC (aPDAC) cohort, 36.0% (n=50) were KRT81+, 27 36.0% (n=50) were double negative and 28.0% (n=39) were HNF1A+, whereas 60.4% 28 (n=84) were GATA6- and 39.6% (n=55) were positive for GATA6. In the resected PDAC 29 (rPDAC) cohort, 39.9% (n=164) were KRT81+, 43.6% (n=179) were double negative and 30 16.5% (n=68) were HNFA1+, whereas 41.1% (n=169) displayed GATA6 expression and 31 58.9% (n=242) were GATA6- (figure 1A). Tumors displaying expression of both KRT81 and 32 HNF1A (double positive), which was the case in 16.5% of the samples in the aPDAC cohort 33 and 7.1% in the rPDAC cohort, were categorized according to the marker showing a 34 predominant expression pattern. This approach was backed by highly similar prognostic 35 implications of the thus assessed subtypes in the double positive cases compared to the 36 single positive ones (suppl. table S1). Both subtyping systems overlapped widely in both cohorts (χ^2 p<0.001 each), with the HNF1A+ subtype being mostly GATA6+ (suppl. table 37

4

1 S2). However, a significant proportion of KRT81+ samples displayed GATA6 expression in 2 both cohorts and no clear trend towards a GATA6-based subtype was observed for the 3 double negative samples, which were rather GATA6- in the aPDAC cohort and rather 4 GATA6+ in the rPDAC cohort (figure 1B and C). For both systems, the assessment of each 5 tumors subtype remained remarkably stable when several tumor tissue punches from 6 different FFPE blocks were compared separately (suppl. table S3).

7 To assess how metastatic progression may affect the tumors subtype, we examined to which 8 extent the primary tumors' and the metastatic tissues' subtypes were interrelated in 9 synchronous and metachronous metastases to its corresponding primary in 57 cases. There 10 was a strong correlation between the primaries' and the metastases' subtype (p=0.001), but we observed a subtype switch according to KRT81 / HNF1A expression in 18 cases (31.6%). 11 12 This was not associated to synchronous or metachronous metastasis (suppl. table S4) but 13 came with a highly significant trend towards a prognostically more favorable subtype (suppl. 14 Table S5). More than half (n=28) of the n=41 KRT81+ cases remained KRT81+ in their 15 corresponding metastasis, the rest was mostly double negative and only three cases 16 switched to HNF1A+. Double negative cases mostly remained double negative during 17 metastasis, whereas the few (n=3) HNF1A+ cases split between KRT81 positivity and 18 HNF1A positivity in their metastatic tissue (figure 1 D, suppl. table S6). In contrast, the 19 transcriptional subtype according to GATA6 expression remained stable in most cases with 9 20 of 34 cases switching from GATA6- to GATA6+ and 7 of 23 cases switching from GATA6+ to 21 GATA6- (figure 1 E, suppl. table S6). Here, subtype switching occurred more frequently in 22 synchronous metastases (suppl. table S4). Neither the primary tumors' nor the metastases 23 subtype or the occurrence of a subtype switch was associated with metastasis localization 24 (suppl. table S7).

25

Transcriptional subtypes affect patient outcome dependent on palliative therapy in advanced PDAC patients

28 The baseline characteristics, outcome and clinicopathological variables of the aPDAC patient 29 cohort were previously described⁸. In the unstratified cohort, transcriptional subtypes 30 according to KRT81/HNF1A expression implied a statistically non-significant trend for patient 31 OS, with HNF1A+ cases having the best, double negative cases an intermediate and 32 KRT81+ the worst outcome (OS 6.8 vs. 9.1 vs. 10.7 months, p= 0.08, HR=1.27 95%, CI 1.02 33 - 1.59, suppl. figure S2 A), which was not reflected in PFS times (PFS 3.6 vs. 4.1 vs. 6.4 34 months, p= 0.42, HR=1.16 95% CI 0.91 – 1.48, suppl. figure S2 B). Similarly, subtyping 35 based on GATA6 expression had no prognostic impact in the unstratified patient cohort (PFS 36 4.2 vs 4.3 months, p= 0.43, HR 1.16 95%CI 0.80 - 1.69; OS 7.8 vs. 9.2 months, p=0.76, HR 37 1.06, 95% CI 0.74 – 1.51, suppl. figure S2 C, D). As expected, only KRT81/ HNF1A based

1 subtypes showed a trend towards statistical significance in multivariate analyses (p=0.07, suppl. table S8) and transcriptional subtypes were not associated with the patients 2 3 clinicopathological variables (table 1). Stratification of patient subgroups according to the applied type of 1st line palliative treatment, revealed a significant impact of the tumors 4 transcriptional subtype on patient outcome, as patients with double negative tumors derived 5 6 the most benefit from palliative gemcitabine-based chemotherapy (pGC) compared to 7 palliative non-gemcitabine-based chemotherapy (pnGC, PFS 6.3 vs 2.4 months, p<0.001, 8 HR 0.26, 95%CI 0.13 – 0.52; OS 9.6 vs 5.7 months, p=0.04, HR 0.53, 95%CI 0.29 – 0.97, 9 figure 2 A,B). Similarly, patients with KRT81+ tumors showed favorable PFS times with pGC 10 compared to pnGC (PFS 4.5 vs. 2.2 months, p=0.02, HR 0.43, 95%CI 0.21 - 0.90 figure 2 11 A), but no significant impact of palliative chemotherapy on OS times (OS 6.8 vs 4.7 months, 12 p=0.47, HR 0.78 95%CI 0.40 - 1.52, figure 2 B). Interestingly, the type of palliative 13 chemotherapy had no significant prognostic impact in patients with HNF1A+ tumors (pnGC vs. pGC, PFS 6.6 vs. 2.7 months, p=0.28, HR 0.65 95%CI 0.30 - 1.42; OS 13.2 vs. 9.3 14 months, p=0.60, HR 0.82, 95%CI 0.38 - 1.75 figure 2 A, B), which was also confirmed in 15 16 multivariate analyses (suppl. table S9). Applying the GATA6-based subtypes paralleled these 17 findings, as patients with GATA6- tumors profited from pGC compared to pnGC, whereas no 18 significant prognostic impact of the type of palliative chemotherapy was detected for patients with GATA6+ tumors (GATA6- PFS 9.3 vs 2.4 months, p<0.001, HR 0.27, 95%CI 0.15 -19 20 0.48; OS 9.7 vs 7.2 months, p=0.04, HR 0.60, 95%CI 0.38 - 0.97; GATA6+ 5.0 vs 2.7 21 months, p=0.21, HR 0.65 95%CI 0.33 – 1.29; OS 7.8 vs 4.9 months, p=0.34, HR 0.72 95%CI 22 0.37 – 1.42, figure 2 C,D), which was confirmed for PFS in multivariate analyses (suppl. table 23 S9).

24

Transcriptional subtypes affect patient outcome dependent on adjuvant therapy in resected PDAC patients

27 In the unstratified rPDAC cohort, there was a statistically non-significant impact of the 28 tumors' subtype on outcome, with KRT81 positivity conferring the worst, double negative an 29 intermediate and HNF1A positivity the best outcome (OS 17.1 vs. 19.3 vs. 22.3 months, 30 p=0.34, HR 0.87, 95% CI 0.81 – 0.94; DFS 9.7 vs. 12.1 vs. 12.4 months, p= 0.47, HR 1.08, 31 95%CI:0.90 - 1.28, suppl. figure S3 A, B), which turned out as independent prognostic 32 marker for OS in multivariate analyses (suppl. table S 10). Similarly, GATA6 expression was 33 associated with a statistically not significant trend towards better prognosis (OS 20.7 vs. 15.2 34 months, p=0.20, HR 0.87, 95% CI 0.69 – 1.08, suppl. figure S3 C) but showed no tendency 35 for differences in DFS (suppl. figure S3 D) although it turned out as independent 36 prognosticator for OS in multivariate analyses (p=0.006, HR 0.73, 95%CI 0.58 - 0.91, suppl. 37 table S10). Transcriptional subtypes were not associated to the patients clinicopathological

1 parameters (table 2). To test the impact of subtyping on response to adjuvant chemotherapy 2 we calculated DFS and OS times in each subtype according to the application of adjuvant 3 gemcitabine-based chemotherapy (aGC) compared to no or non-gemcitabine-based 4 adjuvant chemotherapy (naGC). Interestingly, the prognostically worst KRT81+ subtype, had the strongest prognostic impact of adjuvant gemcitabine-based chemotherapy (DFS 5.0 vs. 5 6 13.7 months, p<0.001, HR 0.37, 95% CI 0.25 – 0.55; OS 8.3 vs. 31.6 months, p<0.001, HR 7 0.26 95%Cl 0.18 - 0.37), whereas this was not the case for the double negative subtype 8 (DFS 10.1 vs. 13.5 months, p= 0.52, HR 0.88, 95%CI 0.59 – 1.32; OS 17.7 vs. 21.0 months, 9 p=0.08, HR 0.76, 95%CI 0.54 – 1.07) or the HNF1A+ subtype (DFS 12.8 vs. 9.5 months, p=0.39, HR 1.32, 95%CI 0.70 - 2.49; OS 20.4 vs. 23.4 months, p=0.38, HR 0.78, 95%CI 10 0.45 – 1.36, figure 3 A,B). Similar results were obtained for GATA6-based subtyping, where 11 12 the GATA6- subtype profited significantly from adjuvant gemcitabine-based chemotherapy 13 (DFS 4.8 vs. 15.1 months, p<0.001, HR 0.30, 95%CI 0.19 – 0.46; OS 7.0 vs. 32.2 months, 14 p<0.001, HR 0.21, 95%CI 0.66 – 1.18), whereas it was not beneficial in the GATA6+ subtype 15 (DFS 10.5 vs. 10.0 months, p=0.62, HR 1.09, 95%CI 0.78 – 1.51; OS 18.9 vs. 21.5 months, 16 p= 0.42, HR 0.87, 95%CI 0.66 – 1.18, figure 3 C,D). These findings were also reflected in 5-17 year-survival rates (suppl. table S11). We confirmed these findings in multivariate analyses 18 which also demonstrated the prognostic impact of the patients' clinicopathological 19 characteristics in each subtype. Interestingly, the R-status was most important for DFS and 20 OS in the KRT81+ and GATA6- subtypes, whereas in the HNF1A+ and the GATA6+ 21 subtypes pN-stage had the strongest prognostic influence (suppl. table S11).

We validated these findings in two independent publicly available PDAC cohorts (n=138 and n=178) with corresponding RNAseq-based gene expression data. In both datasets, just as in our cohort, patients with KRT81+ or GATA6- tumors derived the most benefit from gemcitabine-based adjuvant chemotherapy, whereas in the other subtypes the impact of aGC was minor (suppl. figure S4).

27 To explore a potential mechanistic background for the observed gemcitabine-resistance in 28 the patients with HNF1A+/ GATA6+ tumors, we tested the association of the expression of 29 HNF1A, KRT81 and GATA6 with the expression of gemcitabine-resistance associated genes 30 in the same RNAseq-based gene expression datasets. In both cohorts, there was a strong 31 positive correlation with HNF1A and GATA6 expression and an inverse correlation for KRT81 32 with the expression of ABCC3 and MVP, both known to cause gemcitabine-resistance in vitro and *in vivo*^{12,13} (suppl. figure S5). Of note, after adjusting for multiple testing, transcriptional 33 34 subtypes did not correlate with specific molecular alterations on the genomic level (suppl. 35 figure S6).

36

37 DISCUSSION

1 Transcriptional subtyping in pancreatic cancer using different systems of hallmark genes and detection techniques and its potential clinical or biological impact has been reported several 2 times to date ^{5-7,9,14-25} (table 3). There is a certain consensus that there are at least two 3 subtypes, mostly termed "basal" or "quasi-mesenchymal" and "classical"²⁶. Whereas the first 4 one is often associated with poorer outcome and sometimes higher tumor grade, exemplified 5 by the adenosquamous subtype of PDAC, the latter is associated with better prognosis and 6 better therapy response to FOLFIRINOX (FFX)^{14,27}. Other previously proposed transcriptional 7 subtypes, such as the so called "immunogenic" or "ADEX" subtype by Bailey et al (QUOTE), 8 could not be reproduced entirely by other groups ²⁸. Thus, their existence remains a matter of 9 10 debate to date. None of the previously published studies on transcriptional subtyping in 11 PDAC examined their predictive impact on currently still widely employed therapies. 12 Moreover, none of the IHC-based subtyping systems were compared in the same set of 13 patient samples as yet and a potential subtype switch during metastatic progression -which 14 eventually occurs in the majority of PDAC patients- has not been examined either. In this 15 study, we employed and compared the two most widespread subtyping systems based on 16 the robust immunohistochemical detection of KRT81, HNF1A or GATA6. We show that both 17 systems overlap widely and can be employed equally, which offers a cost efficient approach 18 to personalized cancer therapy as specific subtypes respond differentially to therapy. For 19 instance, patients with KRT81+ / GATA6- tumors profit better from gemcitabine-based 20 chemotherapy in the palliative but also the adjuvant setting compared to their KRT81-/ GATA+ counterparts in our cohorts, which is backed by previously published data ^{6,29}. Thus, 21 22 transcriptional subtyping by IHC could be used to inform therapy decisions in the routine 23 clinical setting, even in cases with scarce or low-quality tumor material in which RNA-based 24 approaches tend to fail. Our approach to categorize according to the most dominant subtype 25 in the KRT81/HNF1A system, resolved the issue of double positive cases, which were excluded from analysis in previously published studies ^{5,7,22,23}. Our novel finding that 26 27 transcriptional subtypes may switch during metastatic progression may explain differential 28 therapy responses of primary tumors and metastases and implies a rationale to re-biopsy 29 metastatic tissue to inform a subtype-based therapy choice. We also show that the R-status 30 has a much stronger prognostic impact in KRT81+ / GATA6- tumors. Thus, in this subtype, it 31 is much more important to achieve a wide R0-resection compared to others, which should be 32 considered during resection and may justify a more aggressive surgical approach.

Its retrospective nature and the fact that no patients treated with more active regimens like FFX were included in the analyses are limitations of our study. However, not only in the adjuvant setting but also in advanced disease, most patients are still treated with gemcitabine-based chemotherapy regimens to date, as co-morbidities and frailty preclude the application of potentially more efficient but more toxic regimens like FFX ³⁰, which in real world data not necessarily prove to be superior to gemcitabine-based regimens ^{31,32}. Thus, in
the present study we propose a simple and robust diagnostic tool for therapeutic decision
making in routine clinical practice. Physicians should be aware of a potential subtype switch
during disease progression, which justifies a re-biopsy of metastatic lesions.

- 5
- 6
- 7
- 8

9 ADDITIONAL INFORMATION

10 Ethics approval and consent to participate

Each patient gave written informed consent for the use of its tumor material and clinical data for academic research purposes upon study enrollment. Ethical approval by the local ethics committee was given for each study ^{33,34} and they were carried out according to the Declaration of Helsinki. The non-commercial academic use of anonymized patient data and corresponding tumor material was approved by the ethics committee of the medical faculty of Ludwig-Maximilians-University without obtaining the patients' informed consent (project numbers 554-11, 401-15, 20-081, 23-0222 and 23-0224).

18

19 Availability of data and materials

- 20 The expression datasets used for validation are publicly accessible on
- 21 https://portal.gdc.cancer.gov/ and https://dcc.icgc.org/.
- 22 Raw data on the patient cohorts employed in this study can be obtained from the
- 23 corresponding author upon reasonable request.
- 24

25 Competing interests

- 26 All authors declare no conflict of interest related to the present study.
- 27

28 Funding

- 29 This study did not receive any funding.
- 30

31 Author contributions

- 32 MG and SO read and scored immunohistochemical stainings, performed statistical analyses,
- 33 drafted figures and wrote the manuscript. SAS analyzed bioinformatic data and drafted
- figures. VH, MH and SB provided clinical patient data and /or patient material. All authors read and reviewed the manuscript.
- 36

37 Acknowledgments

- 1 We thank Andrea Sendelhofert and Anja Heier for excellent technical assistance and all
- 2 study participants and their families for supporting our research.
- 3

4 References

Park, W., Chawla, A. & O'Reilly, E. M. Pancreatic cancer: a review. Jama 326, 851-1 5 6 862 (2021). 7 2 Guenther, M. et al. The impact of adjuvant therapy on outcome in UICC stage I 8 pancreatic cancer. International Journal of Cancer 151, 914-919 (2022). 9 3 Tempero, M. A. et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical 10 practice guidelines in oncology. Journal of the National Comprehensive Cancer Network 19, 439-457 (2021). 11 12 4 Collisson, E. A., Bailey, P., Chang, D. K. & Biankin, A. V. Molecular subtypes of pancreatic cancer. Nature reviews Gastroenterology & hepatology 16, 207-220 13 14 (2019). 5 15 Noll, E. M. et al. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma. Nature medicine 22, 278-287 (2016). 16 Martinelli, P. et al. GATA6 regulates EMT and tumour dissemination, and is a marker 17 6 18 of response to adjuvant chemotherapy in pancreatic cancer. Gut 66, 1665 (2017). 19 7 Muckenhuber, A. et al. Pancreatic Ductal Adenocarcinoma Subtyping Using the 20 Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clin Cancer Res 24, 351-359 (2018). 21 8 22 Guenther, M. et al. TPX2 expression as a negative predictor of gemcitabine efficacy 23 in pancreatic cancer. British Journal of Cancer, 1-8 (2023). 24 9 Kruger, S. F. et al. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-25 26 YMO-PAK-0515 study. ESMO Open 7, 100388 (2022). 10 Zhang, J. et al. The international cancer genome consortium data portal. Nature 27 28 biotechnology 37, 367-369 (2019). 29 11 Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring 30 multidimensional cancer genomics data. Cancer discovery 2, 401-404 (2012). 31 12 Zhao, Y. et al. ABCC3 as a marker for multidrug resistance in non-small cell lung 32 cancer. Scientific reports 3, 3120 (2013). 13 Yu, X. et al. CD73 induces gemcitabine resistance in pancreatic ductal 33 34 adenocarcinoma: A promising target with non-canonical mechanisms. Cancer Letters 35 519, 289-303 (2021). 36 14 O'Kane, G. M. et al. GATA6 Expression Distinguishes Classical and Basal-like 37 Subtypes in Advanced Pancreatic Cancer. Clin Cancer Res 26, 4901-4910 (2020). 38 15 Duan, K. et al. The value of GATA6 immunohistochemistry and computer-assisted 39 diagnosis to predict clinical outcome in advanced pancreatic cancer. Sci Rep 11, 40 14951 (2021). 16 de Andrés, M. P. et al. GATA4 and GATA6 loss-of-expression is associated with 41 42 extinction of the classical programme and poor outcome in pancreatic ductal 43 adenocarcinoma. Gut (2022). 17 Beutel, A. K. et al. A Prospective Feasibility Trial to Challenge Patient-Derived 44 Pancreatic Cancer Organoids in Predicting Treatment Response. Cancers (Basel) 13 45 46 (2021). 47 18 Shoucair, S. et al. GATA6 and Keratin5 Expression Profile is a Reliable Biomarker for 48 Prediction of Improved Survival with Adjuvant Chemotherapy after Surgical Resection 49 in PDAC. HPB 24, S75 (2022). 50 19 Heredia-Soto, V. et al. The Relationship between the Expression of GATA4 and GATA6 with the Clinical Characteristics and Prognosis of Resectable Pancreatic 51 Adenocarcinoma. Biomedicines 11, 252 (2023). 52

1	20	Park, E. et al. Combined tumor epithelial and stromal histopathology with keratin 81
2		expression predicts prognosis for pancreatic ductal adenocarcinoma. J Hepatobiliary
3		Pancreat Sci 29 , 250-261 (2022).
4	21	Lu, Y. et al. HNF1A inhibition induces the resistance of pancreatic cancer cells to
5		gemcitabine by targeting ABCB1. <i>EBioMedicine</i> 44 , 403-418 (2019).
6	22	Kaissis, G. et al. A machine learning algorithm predicts molecular subtypes in
7		pancreatic ductal adenocarcinoma with differential response to gemcitabine-based
8		versus FOLFIRINOX chemotherapy. PloS one 14, e0218642 (2019).
9	23	Kaissis, G. A. et al. Multiparametric Modelling of Survival in Pancreatic Ductal
10		Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived
11		Parameters. Journal of Clinical Medicine 9, 1250 (2020).
12	24	Peng, L. et al. Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates
13		with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in
14		Pancreatic Adenocarcinomas. Cancers 15, 1587 (2023).
15	25	de Andrés, M. P. et al. GATA4 and GATA6 loss-of-expression is associated with
16		extinction of the classical programme and poor outcome in pancreatic ductal
17		adenocarcinoma. <i>bioRxiv</i> (2021).
18	26	Singh, S., Hasselluhn, M. C. & Neesse, A. A tangled tale of molecular subtypes in
19		pancreatic cancer. <i>Gut</i> 68 , 953-954 (2019).
20	27	Birnbaum, D. J., Finetti, P., Birnbaum, D., Mamessier, E. & Bertucci, F. Validation and
21		comparison of the molecular classifications of pancreatic carcinomas. Molecular
22		<i>cancer</i> 16 , 1-7 (2017).
23	28	Maurer, C. et al. Experimental microdissection enables functional harmonisation of
24		pancreatic cancer subtypes. <i>Gut</i> 68 , 1034-1043 (2019).
25	29	Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their
26		differing responses to therapy. Nat Med 17, 500-503 (2011).
27	30	Hegewisch-Becker, S. et al. Results from the prospective German TPK clinical cohort
28		study: treatment algorithms and survival of 1,174 patients with locally advanced,
29		inoperable, or metastatic pancreatic ductal adenocarcinoma. International journal of
30		<i>cancer</i> 144 , 981-990 (2019).
31	31	Santucci, J. et al. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel
32		chemotherapy on survival in advanced pancreatic cancer: Evidence from the
33		prospective international multicentre PURPLE pancreatic cancer registry. European
34		Journal of Cancer 174 , 102-112 (2022).
35	32	Riedl, J. M. et al. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-
36		line treatment of advanced pancreatic cancer: A propensity score analysis. European
37		Journal of Cancer 151 , 3-13 (2021).
38	33	Haas, M. et al. Extended RAS analysis and correlation with overall survival in
39		advanced pancreatic cancer. British journal of cancer 116 , 1462 (2017).
40	34	Heinemann, V. et al. Gemcitabine plus erlotinib followed by capecitabine versus
41		capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer:
42		final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische
43		Onkologie'(AIO-PK0104). <i>Gut</i> 62, 751-759 (2013).
44		
45	Figur	e legends and table titles
46	Figur	re 1
17	-	rantial expression of KRT81 HNE1A and GATA6 in pancreatic cancer

47 Differential expression of KRT81, HNF1A and GATA6 in pancreatic cancer

48 Immunohistochemical detection of KRT81, HNF1A and GATA6 expression in exemplary

49 PDAC samples. 200-fold magnification. Scale bar indicates 50 μm (A). Comparison of the

- 50 tumors' transcriptional subtypes based on the expression of KRT81 / HNF1A or GATA6 in
- 51 advanced (B) and resected PDAC (C) as well as between the primary tumor and its

1 corresponding metastasis using subtyping based on KRT81 / HNF1A-expression (D) or

2 GATA6-expression (E).

3

4 Figure 2

- 5 Transcriptional subtypes are associated with therapy response in 1st line gemcitabine treated
- 6 advanced pancreatic cancer patients
- 7 Univariate analyses (Kaplan-Meier curves and log-rank tests) for PFS and OS in the
- 8 subtypes based on KRT81 / HNF1A expression stratified by 1st line chemotherapy (A, B) as
- 9 well as in the subtypes based on GATA6 expression stratified by 1st line chemotherapy (C,
- 10 D). Crossed lines indicate censored cases.
- 11

12 Figure 3

- Transcriptional subtypes are associated with therapy response in resected pancreatic cancer
 patients treated with adjuvant gemcitabine-based chemotherapy
- 15 Univariate analyses (Kaplan–Meier curves and log-rank tests) for DFS and OS in the 16 subtypes based on KRT81 / HNF1A - expression stratified by gemcitabine-based adjuvant
- subtypes based on KRT81 / HNF1A expression stratified by gemcitabine-based adjuvant
- 17 treatment (A, B) and in the subtypes based on GATA6 expression stratified by gemcitabine-
- 18 based adjuvant treatment (C, D). Crossed lines indicate censored cases.
- 19

20 21 **Table titles**

22 Table 1

- Clinicopathological patient characteristics according to KRT81 / HNF1A expression and
 GATA6 expression in the aPDAC cohort.
- 25

26 **Table 2**

- 27 Clinicopathological patient characteristics according to KRT81 / HNF1A expression and
- 28 GATA6 expression in the rPDAC cohort.
- 29

30 Table 3

31 Study overview on transcriptional subtyping in PDAC

32

- 3334 Supplemental figure legends
- 35 Figure S1
- 36 Expression of KRT81, HNF1A and GATA6 in non-neoplastic tissues

KRT81 expression in normal human tonsil (A), HNF1A expression in normal human small
 bowel mucosa (B) and GATA6 expression in normal human non-neoplastic pancreatic ducts
 (C). 200-fold magnification. Scale bars indicate 50 µm.

4

5 Figure S2

6 Transcriptional subtypes are associated with prognosis in advanced pancreatic cancer 7 patients

8 Univariate analyses (Kaplan–Meier curves and log-rank tests) for PFS and OS in the
9 subtypes based on KRT81 / HNF1A expression (A, B) as well as in the subtypes based on
10 GATA6 expression (C, D). Crossed lines indicate censored cases.

11

12 Figure S2

13 Predominance of the transcriptional subtype affects prognosis in resected pancreatic cancer

14 patients

Univariate analyses (Kaplan–Meier curves and log-rank tests) for OS and DFS in the subtypes based on KRT81 and HNF1A (a, b)

17

18 Figure S3

19 Transcriptional subtypes are associated with prognosis in resected pancreatic cancer 20 patients

Univariate analyses (Kaplan–Meier curves and log-rank tests) for PFS and OS in the subtypes based on KRT81 / HNF1A expression (A, B) as well as in the subtypes based on

23 GATA6 expression (C, D). Crossed lines indicate censored cases.

24

25 Figure S4

26 Transcriptional subtype is associated with therapy response in resected pancreatic cancer

27 patients treated with adjuvant gemcitabine-based chemotherapy

28 Univariate analyses (Kaplan–Meier curves and log-rank tests) for DFS and OS stratified by

29 gemcitabine-based adjuvant treatment of the subtypes based on KRT81 / HNF1A -

30 expression and GATA6 - expression in the TCGA-PAAD cohort (A-D) and in the PACA-CA

31 cohort (E-H). Crossed lines indicate censored cases.

32

33 Figure S5

34 Transcriptional subtypes show differential expression of gemcitabine-resistance promoting 35 genes

- 36 Spearman correlations (scatter plots) of log2 mRNA expression between GATA6, HNF1A
- and KRT81 with ABCC3 or MVP across the TCGA-PAAD firehose dataset (A F) as well as

1	the ICGC-CA firehose dataset (G - L, *P < 0.05; **P < 0.01,***P < 0.0001; n.s., not
2	significant; Spearman (two-tailed)).
3	
4	Figure S6
5	KRT81 / HNF1A- or GATA6-based transcriptional subtypes are not associated with specific
6	molecular alterations in pancreatic cancer
7	Oncoprint for the ten most common genetic alterations in the subtypes based on KRT81 /
8	HNF1A - expression (A) and GATA6 - expression (B).
9	
10	
11	Supplemental table titles
12	
13	Table S1
14	Prognostic impact of the predominant transcriptional subtype in advanced and resected
15	PDAC patients.
16	
17	Table S2
18	Comparison of both subtyping systems in the advanced and the resected PDAC cohorts.
19	
20	Table S3
21	Assessment of transcriptional subtypes in different tissue samples for KRT81 / HNF1A (A)
22	and GATA6 (B).
23	
24	Table S4
25	Subtype changes during disease progression.
26	
27	Table S5
28	Comparison of primary tumor subtype with metastatic occurrence and subtype changes for
29	KRT81 / HNF1A and GATA6.
30	
31	Table S6
32	Transcriptional subtypes in primary tumors and corresponding metastasis.
33	
34 25	Table S7 Metastatic localization, primary tumor subtype and occurence of subtype change.
35 36	
36 37	Table S8
57	

- 1 Multivariate Cox regression analysis of PFS- and OS-associated factors in the advanced
- 2 pancreatic cancer study cohort.
- 3

4 Table S9

5 Multivariate Cox regression analysis of PFS- and OS-associated factors in the aPDAC cohort

- 6 stratified for subtypes.
- 7

8 **Table S10**

9 Multivariate Cox regression analysis of DFS- and OS-associated factors in the resected10 PDAC cohort.

11

12 Table S11

13 Five-year survival rates in the rPDAC cohort for subtypes based on KRT81 / HNF1A- and

14 GATA6- expression according to adjuvant gemcitabine treatment.


15

16 **Table S12**


17 Multivariate Cox regression analysis of DFS- and OS-associated factors in the rPDAC cohort

18 stratified for transcriptional subtypes.

Figure 1



D



Е

Figure 2






Figure 3

Α








Table 1

Patients clinicopathological variables and transcriptional subtypes in the aPDAC cohort.

		subtype, no (%)	_	subtype		
	KRT81 pos. (n = 50)	double neg. (n = 50)	HNF1A pos. (n = 39)	p-value (χ2- test)	GATA6 neg. (n = 84)	GATA6 pos. (n = 55)	p-value (χ2- test)
sex							
female	30 (60.0)	29 (58.0)	20 (51.3)	0.70	38 (45.2)	22 (40.0)	0.54
male	20 (40.0)	21 (42.0)	19 (48.7)		46 (54.8)	33 (60.0)	
age group							
≤ 60	20 (40.0)	19 (38.0)	18 (46.2)	0.73	33 (39.3)	24 (43.6)	0.61
> 60	30 (60.0)	31 (62.0)	21 (53.8)		51 (60.7)	31 (56.4)	
treatment arm							
non-gemcitabine based	13 (26.0)	18 (36.0)	9 (23.1)	0.35	29 (34.5)	11 (20.0)	0.06
gemcitabine based	37 (74.0)	32 (64.0)	30 (76.9)		55 (65.5)	44 (80.0)	
KPS							
≤ 80	18 (36.0)	19 (38.8)	14 (359)	0.95	32 (38.1)	19 (35.2)	0.73
> 80	32 (64.0)	30 (61.2)	25 (64.1)		52 (61.9)	35 (64.8)	
grade group							
G1-G2	17 (34.0)	23 (46.0)	21 (53.8)	0.16	33 (39.3)	28 (50.9)	0.18
G3-G4	33 (66.0)	27 (54.0)	18 (46.2)		51 (60.7)	27 (49.1)	
stage at therapy start							
locally advanced metastatic	9 (18.0) 41 (82.0)	8 (16.0) 42 (84.0)	7 (17.9) 32 (82.1)	0.96	15 (17.9) 69 (82.1)	9 (16.4) 46 (83.6)	0.82

Table 2

Patients clinicopathological variables and transcriptional subtypes in the rPDAC cohort.

		subtype, no (%)			subty	oe, no (%)	_	
	KRT81-positive	Double-negative	HNF1A-positive		GATA6	GATA6 GATA6 pos.		
	(n=164)	(n=179)	(n=68)	P value (χ2)	neg.(n=169)	(n=242)	(x2)	
sex								
female	72 (43.9)	99 (55.3)	29 (42.6)	0.06	72 (42.6)	128 (52.9)	0.04	
male	92 (56.1)	80 (44.7)	39 (57.4)		97 (57.4)	114 (47.1)		
age group								
≤ 68	91 (55.5)	93 (52.0)	29 (42.6)	0.20	73 (43.2)	125 (51.7)	0.09	
> 68	73 (44.5)	86 (48.0)	39 (57.4)		96 (56.8)	117 (48.3)		
treatment arm, no (%)								
non-gemcitabinebased	79 (48.2)	73 (40.8)	29 (42.6)	0.38	82 (48.5)	99 (40.9)	0.13	
gemcitabinebased	85 (51.8)	106 (59.2)	39 (57.4)		87 (51.5)	143 (59.1)		
UICC stage (2017)					(<i>'</i>	()		
stage IA	6 (3.7)	12 (6.7)	6 (8.8)	0.37	8 (4.7)	16 (6.6)	0.92	
stage IB	33 (20.1)	32 (17.9)	16 (23.5)		33 (19.5)	48 (19.8)		
stage IIA	16 (9.8)	14 (7.8)	5 (7.4)		16 (9.5)	19 (7.9)		
stage IIB	64 (39.0)	54 (30.2)	18 (26.5)		56 (33.1)	80 (33.1)		
stage III	25 (15.2)	41 (22.9)	16 (23.5)		32 (18.9)	50 (20.7)		
stage IV	20 (12.2)	26 (14.5)	7 (10.3)		24 (14.2)	29 (12.0)		
pT (2017)					· · · ·			
pT1a	1 (0.6)	0 (0.0)	2 (2.9)	0.06	0 (0.0)	3 (1.2)	0.36	
pT1b	1 (0.6)	4 (2.2)	0 (0.0)		2 (1.2)	3 (1.2)		
pT1c	11 (6.7)	26 (14.5)	8 (11.8)		14 (8.3)	31 (12.8)		
pT2	104 (63.4)	99 (55.3)	40 (58.8)		106 (62.7)	137 (56.6)		
pT3	46 (28.0)	46 (25.7)	18 (26.5)		46 (27.2)	64 (26.4)		
pT4	1 (0.6)	4 (2.2)	0 (0.0)		1 (0.6)	4 (1.7)		
, pN (2017)		()				()		
pN0	62 (37.8)	71 (39.7)	31 (45.6)	0.18	69 (40.8)	95 (39.3)	0.88	
pN1	68 (41.5)	62 (34.6)	17 (25.0)		61 (36.1)	86 (35.5)		
pN2	34 (20.7)	46 (25.7)	20 (29.4)		39 (23.1)	61 (25.2)		
R-status		,	()			- ()		
0	106 (64.6)	121 (67.7)	48 (70.6)	0.66	108 (63.9)	167 (69.0)	0.28	
1	58 (35.4)	58 (32.4)	20 (29.4)		61 (36.1)	75 (31.0)		
grade group	- ()	()	()					
G1-G2	45 (27.4)	53 (29.6)	23 (33.8)	0.62	51 (30.2)	70 (28.9)	0.78	
G3-G4	119 (72.6)	126 (70.4)	45 (66.2)		118 (69.8)	172 (71.1)	20	

Table 3

Study overview on transcriptional subtyping in PDAC

marker	author	year co	whort clinical situation			n method	antibodies, dilution	tissue type	scoring method	cutoff definition	results	cohort stratification based on therapy	clinical relevance/conclusion
GATA6	Martinelli	2017	1 resected	313	7th	IHC	polycional goat anti-GATA6 antibody (catalog no. AF1700, R&D Systems) ditution 1:1000	TMA	high, medium, low	NR	GATA6 high: 155 (49%) GATA6 medium: 121 (39%) GATA6 low: 37 (12%)	5FU / leucovorin vs. gemcitabine	borderline predictive for SFU / leucovorin, not for gemcitabine correlates with tumor diffentiation.
	O'Kane	2021	1 advanced stage	106	NA	ISH, IHC	polycional goat anti-GATA6 antibody (catalog no. AF1700, R&D Systems) diution 1:1000	resections, biopsies	semiquantitative score (1-4)	score 1: weak nuclear staining in at least 5% tumor cells score 2: moderate nuclear staining in the tumor score 3: storog nuclear immunopositivity score 4. very storog and diffue staining	GATA6 high: 78 (74%)	NR	prognostic IHC correlates with ISH
	Duan	2021	1 advanced stage	130 (106 patients already reported by O'Kane et al.)	NA	HC	polycional goat anti-GATA6 antibody (catalog no. AF1700, R&D Systems) diution 1:1000	biopsies, whole mou	nt low / high	low: semiquantitative score 1-2 high: semiqunatitative score 3-4	GATA6 high: 73 (56%)	modified FOLFIRINOX vs. gemoitabine-nab- paclitaxel. 10 patients did not receive any treatme	t precitive for mFOLFRINOX but not for gemcitabine/nab-pacilitaxel digital assessment may improve scoring.
	de Andrés	2021	1 resected	745 (282 patients from the ESPAC-3 trial already reported by Martinelli et al. 2017)	7th	HC	polycional goat anti-GATA6 antibody (R&D systems, AF1700, 0.2ug/mL) dilution NR	TMA	low / high	histoscore quantification (proportion of positive tumor cells multiplied by intensity from 0 to 3) [ow: Histoscore < 150 hidr: Histoscore ≥ 150		NR	prognostic
	Beutel	2021	1 advanced stage	25 PDO and 21 corresponding tissue from liver metastases	NA	IHC	monoclonal rabbit anti-GATA6 antibody (clone D61E4, Cell Signaling Technology) dilution 1:100	PDO's, biopsies	NR	NR	GATA6 high tissue: 18 (85.7%) GATA6 high PDO: 19 (76.0%)) NR	not prognostic (PFS) differential expression between tissue and PDO in 4/21 (19%).
	Shoucair	2022	1 resected	76	NR	IHC	NR	NR	low/high	NR	GATA6 high: 36 (47.3%)	adjuvant treatment vs. no adjuvant treatment	predictive for adjuvant therapy
	Heredia-Soto	2023	1 resected	89	7th	IHC	polyclonal goat anti-GATA6 antibody (catalog no. AF1700, R&D Systems) dilution NR	TMA	lowhigh	histoscore quantification (proportion of positive tumor cells multiplied by intensity from 0 to 3) low: Histoscore < 30 high: Histoscore > 30	GATA6 high: 72 (81%)	only adjuvant gemcitabine treated patients include	PanIN and tumor tissue comparable
			1 resected	411	8th			тма			GATA6 positive 169 (41.1%)	gemcitabine-based vs. non gemcitabine-based	no relevant associations to clinicopathological variables prognostic in resected PDAC predictive for gemcitabine-based adjvant treatment
	Guenther	2024				HC	polycional rabbit anti-GATA6 antibody (PA1-104, Thermo Fisher, Germening, Germany) diudion 1:200		negative / positive	tumors with distinct nuclear staining were considered GATA6 positive			influences the role of clinicophatological variables such as R-status not prognostic. Predictive for gemcitabine-based paliative treatment
					NA 8th	_		TMA TMA				gemcitabine-based vs. non gemcitabine-based	no associations to clinicopathological variables.
KRT81			0 1000000	51		HC		TMA			KRT81+: 30 (28%)	NR	may change during metastatic progression. prognostic
	Deels		2 resected neoadiuvant treatment			HC	mouse monoclonal anti-keratin 81 antibody (catalog no. SC-100929, Santa Cruz Biotechnology Inc.)	TMA		WDT04 and 2 with a 2000 WDT04 and an a start and a start	DP: NR KRT81+: 30 (25%)	NR	corrrelates with reduced gland formation
	Park	2022	, 				dilution 1:500		negative / positive	"KRT81-positive": >30% KRT81 expressing tumor cells	DP: NR KRT81+:24(44%)		associated with remaing residual tumor
			advanced disease n= 43	55	8th	IHC		NR			NA: 18 (33%)	NR	prognostic
HNF1a	Lu	2019	1 resected	128	8th	IHC	rabbit anti-HINF1A antibody (catalog no. ab96777, Abcam) diution 1:200	NR	semiquantitative score according to IRS	low: 0-2 moderate: 3-6 high: 8-12	HNF1A high: 21 (16%)	NA	predictive for gem citabine.correlates with stage and Pn1
			1 resected	108	8th			TMA			HNF1A+: 35 (32%) DP:NR	NR	not prognostic corrrelates with increased gland formation
	Park	2022	2 resected neoadjuvant treatment a resected n=12		8th	HC	anti-HNF 1A antibody (catalog no. ab96777, Abcam), dilution1:500	TMA	negative / positive	"HNF1A-positive": nuclear expression, any intensity, moderate or strong intensity, ≥ 5% of cells	NR	NR	not associated with remaining residual tumor
			advanced disease n= 43	55	8th			TMA			NR	NR	NR
HNF1a+ KR	T81 Nol	2016	1 resected	231	7th	IHC	mouse monoclonal anti-keratin 81 antibody (catalog no. sc-100929, Santa Cruz Biotechnology Inc.) difution NR nabbit polyclonal anti-HNF1A antibody (catalog no. sc-8986, Santa Cruz Biotechnology Inc.) difution NR	TMA	negative / positive	"KRT81-positive": detectable staining regardless of signal strength / number of positive cells, strong expression, >10% KRT81 expressing tumor cells "HNF1A-positive": detectable staining regardless of signal strength / number of positive cells, double positive cases excluded	DN: 92 (40%), KRT81+: 79 (34%) HNF1A+: 46 (20%) DP: 14 (6%)	NR	prognostic (HNF1A / KRT81). correlates with grading.
			1 resected	262	7th		mouse monoclonal anti-keratin 81 antibody (catalog no. sc-100929, Santa Cruz Biotechnology Inc.) ditution 1200 nabbit polyclonal anti-HNF1A antibody (catalog no. sc-8986, Santa Cruz Biotechnology Inc.) ditution 1200	TMA	negative / positive	"KRT81-positive": >30% KRT81 expressing tumor cells "HNF1A-positive": medium to strong nuclear staining of HNF1A double positive cases excluded	DN: 165 (63%), KRT81+: 59 (23%) HNF1A+: 35 (13%) DP: 3 (1%)	adjuvant treatment vs. no adjuvant treatment	prognostic (HNF1A / KRT81) correlates with sex
	Muckenhuber	2018	1 resected	130	7th	HC	mouse monoclonal anti-keratin 81 antibody (catalog no. sc-100929, Santa Gruz Biotechnology Inc.) ditution 1.500	TMA	NR	NR	DN: 41 (32%), KRT81+: 21 (16%) HNF1A+: 50 (39%) DP: 18 (13%)	adjuvant treatment vs. no adjuvant treatment	prognostic (HNF1A / KRT81) no correlation to clinicopathological variables
			1 advanced stage	125	NA		rabbit polyclonal anti-HNF1A antibody (catalog no. sc-8986, Santa Cruz Biotechnology Inc) diution 1:100	TMA	NR	NR	DN: 62 (50%), KRT81+: 11 (9%) HNF1A+: 47 (38%) DP: 5 (3%)	gemoitabine-based vs. FOLFIRINOX-based	prognostic (HNF1A / KRT81) no correlation to clinicopathological variables HNF1A+ increased initial tumor control in folfininox-based treatment
	Kaissis	2019		55 (21 Patients derived from Muckenhuber et al.)	7th	HC	according to Muckenhuber et al.	NR/TMA	according Muckenhuber et al.	according to Muckenhuber et al. double negative and double positive cases were excluded	KRT81+: 27 (49%) DN: NR HNF1A+: 28 (51%) DP: NR	FOLFRNOX-based palliative treatment vs. gemcitabine-based palliative treatment	prognostic no correlation with clinicopathological variables KRT81- predictive for palilative FOLFIRINOX. KRT81+ predictive for palilative gemcitabine
	Kaissis	2020	1 resected	103 (patients derived from Muckenhuber et al.)	7th	HC	according to Muckenhuber et al.	NR/TMA	according Muckenhuber et al.	according to Muckenhuber et al.	KRT81+: 16 (15.5%) DN: NR HNF1A+: NR DP: NR	NR	prognostic
	Kruger	2022	1 resected	71	7th	нс	anti-KRT81 (done 3810,5810, LS Bin, Swattle, WA) diuliun 1:120 polycional rabbit anti-NPF1A (Allas antibodies, Slockholm, Sweden) diulion 1:100	resections	negative / positive	"NNF1A-positive": strong and specific nuclear staining "KRT81-positive": strong and specific membranous and cytoplasmatic staring	M1-PUL: KRT81+: 11 (29%) DN: 19 (50%) HNF1A+: 8 (21%) DP: 0 (0%) M1-ANY: KRT81+: 8 (24%) DN: 20 (61%) HNF1A+: 5 (15%) DP: 0 (0%)	NR	no significant differences between isolated lung and other metastatic patter
	Peng	2023	1 resected	57	not sta	ate IHC	mouse monoclonal anti-keratin 81 antibody (catalog no. sc-100929, Santa Cruz Biotechnology Inc.) diudion 1:200 mouse monoclonal anti-HNF1A antibody (catalog no.sc-393925, Santa Cruz Biotechnology Inc)	resections	negative / positive	NR	HNF1A+: 31 (54%) KRT81+: 19 (33%) DN: 7 (12%)	NR	NR
			1 resected	411	8th		diulion 1200	TMA			KRT81+: 154 (37.5) HNF1A+: 49 (11.9) DP: 29 (7.0) DN: 179 (43.6)	gemcitabine-based vs. non gemcitabine-based	prognostic in rPDAC (KRT81 / HNF1A) no associations to clinicopathological variables predictive for adjuvant gemcitabine influences clinicopathological risk factors such as R-status
	Guenther	2024	2 advanced stage	139	NA	HC	ani-KRT81, (done 3810-5810, LS Bio, Seattle, WA) dhulion 1:20 polyclonal rabbit anti-NF1A (Allas antibodies, Stockholm, Sweden) dution 1:100	TMA	negative / positive	samples with 2 30% KRT81- or HNF1A-positive tumor cells: positive for each marker double positive samples categorized according to predominant marker	KRT81+: 38 (27.3%) HNF1A+: 28 (20.1%) DP: 23 (16.6%) DN: 50 (36.0)	gemcitabine-based vs. non gemcitabine-based	Innuences cinicoparinological risk factor's such as R-status not prognostic in aPDAC predictive for genicitatine no relevant associations to clinicopathological variables
		3	3 resected	57	8th			TMA			KRT81+: 39 (68.4%) HNF1A+: 0 (0.0%) DP: 5 (8.8%) DN: 13 (22.8.0)	NA	sublype may change during metastasis no association between changes in tumor differentiation and changes in su